Metastatic cancer

Metastatic cancer to the jaws is the hematogenous deposition of a distant epithelial (rarely non-epithelial) malignancy within the gnathic bones, and it behaves as aggressive, widely disseminated disease rather than a local lesion.[1][2] It is uncommon, accounting for roughly 1% of oral malignancies, but it is the most frequent malignant process to colonize the skeleton generally, and the mandible is far more often involved than the maxilla.[3][4] The dominant primaries are breast (women) and lung (men), followed by kidney, prostate, thyroid, liver, and colon.[1][2][5]

Spread follows the "seed and soil" principle: most deposits reach the jaws through the bloodstream, which is why pulmonary involvement so often coexists, and why the red-marrow–rich posterior mandible is the preferred landing site.[6][7] The signature imaging pattern is an ill-defined, "moth-eaten" osteolytic lesion, though osteoblastic or mixed deposits occur with prostate and some breast and thyroid tumors.[3][4] Management is dictated by the disseminated nature of the disease and is usually palliative, with local therapy reserved for isolated deposits or symptom control.[2][3]

The entity is most accurately termed metastatic carcinoma (or metastatic tumor) to the jawbones, distinguished from metastasis to the oral soft tissues, which has a different site predilection (attached gingiva) and primary-tumor profile.[1][8] Umbrella phrases such as metastasis to the oral and maxillofacial region (MOMR) encompass both compartments and appear widely in the systematic-review literature.[4]

• A metastatic deposit in the jaw is not a primary bone tumor; the correct final diagnosis names both the metastatic nature and the tissue of origin (for example, "metastatic renal cell carcinoma to the mandible").
• When no primary is evident after standard workup, the deposit is classified under cancer of unknown primary (CUP)/occult primary, which carries its own diagnostic algorithm.[9][10]
• Older case reports using purely descriptive labels such as "secondary carcinoma of the jaw" may be encountered; these should not be confused with primary intraosseous carcinoma.

Jaw and oral metastases cluster in older adults, most commonly in the fifth to eighth decades, with a mean age near 56–59 years and an overall male predilection in pooled series.[4][6][11] Sex-specific primary-site patterns are clinically useful:

• Men: lung is the leading primary to the jawbones, followed by prostate, kidney, and bone/adrenal.[1][8]
• Women: breast dominates, followed by adrenal, female genital organs, colorectum, and thyroid.[1][8]

Anatomic distribution is consistent across cohorts:

• Jaws more than soft tissue: bone is involved roughly twice as often as oral soft tissue.[1][12]
• Mandible predominance: classic figures assign about 80% to the mandible, 15% to the maxilla, and 5% to both.[3][4]
• Posterior predilection: the premolar–molar region, angle, and body are favored, mirroring residual hematopoietic marrow; the condyle is occasionally affected.[3][7]

Notably, a jaw deposit is the first sign of a previously unknown malignancy in roughly 23–30% of cases, making the oral clinician an occasional first responder to systemic cancer.[1][3][8]

Presentation is typically rapid in tempo, over weeks to a few months, which helps separate metastasis from indolent odontogenic lesions.[1][6] The core triad for intraosseous deposits is swelling, pain, and paresthesia.[1][2]

• Pain is the single most common symptom and is present in the majority of intraosseous cases; it may be misattributed to odontogenic or temporomandibular sources.[6][13]
• Paresthesia (numb chin/lip) reflects inferior alveolar or mental nerve involvement and is a malignant red flag; it is most often reported with breast carcinoma, followed by lymphoma and prostate carcinoma.[6]
• Tooth mobility, displacement, and unexplained non-healing sockets after extraction are recognized presentations, and rapid post-extraction swelling should prompt suspicion.[13][14]
• Trismus suggests condylar or ramus involvement.[4]
• Gingival/mucosal masses can mimic pyogenic granuloma, peripheral giant cell granuloma, or fibrous epulis, particularly when soft tissue is involved.[1][4]

Red flags warranting urgent investigation include progressive mental-nerve paresthesia, a rapidly enlarging mass, pathologic mobility of sound teeth, pain disproportionate to dental findings, and a non-resolving "post-extraction" swelling—especially in any patient older than 40 years or with a cancer history.[14][15] Because clinical features overlap with benign inflammatory disease, diagnostic delay is common and biopsy is mandatory when presentation is atypical.[1]

Location and distribution

Deposits concentrate in the posterior mandible—premolar–molar region, angle, body, and ramus—corresponding to persistent red marrow; maxillary and condylar lesions are less common.[3][7] Lesions are usually solitary but may be multifocal, and multiplicity is more typical of breast, colorectal, and endometrial primaries.[6]

Relationship to teeth and the alveolar process

Metastasis has no odontogenic epicenter and is not centered on a tooth apex or follicle. Instead it permeates marrow spaces around existing structures, producing periapical-appearing radiolucencies, alveolar bone loss that simulates periodontal disease, and "floating teeth" when supporting bone is destroyed.[3][13]

Periphery and shape

The hallmark periphery is ill-defined, non-corticated, and ragged ("moth-eaten"), without the smooth cortication of cysts or benign tumors.[3][4] Margins are irregular and infiltrative; a well-defined corticated border argues strongly against metastasis.[16]

Internal architecture

Most deposits are radiolucent (reported in roughly 60–76% of imaged cases), reflecting osteoclast-mediated bone destruction.[4][6] Important variants:

• Osteoblastic (radiopaque) or mixed patterns occur, classically with prostate and some breast and thyroid carcinomas.[3][4][7]
• Residual islands of non-resorbed bone can give a patchy, mottled internal appearance rather than a true matrix.[4]

Effects on teeth and adjacent structures

• Widening of the periodontal ligament space and loss/irregularity of the lamina dura are recognized signs of malignant marrow infiltration and overlap with osteosarcoma and hematolymphoid lesions. (These same findings also follow prior head-and-neck radiotherapy, an important confounder in treated patients.)[16][17][18][19]
• "Spiking" or irregular root resorption is less consistent than in some primary lesions but can occur.[16]
• Teeth appear to "float" in a radiolucent field when alveolar support is lost, without corresponding root destruction proportionate to bone loss.[3][13]
• Enlargement of the inferior alveolar canal or mental foramen and effacement of normal cortical lines may accompany neural involvement.[6]

Cortical involvement, growth pattern, and extent

Growth is destructive and permeative rather than expansile; cortical erosion or frank perforation with an associated soft-tissue mass is common and favors malignancy over a cyst.[14][16] A pathologic fracture may be the presenting finding.[20] Periosteal new bone is uncommon, but a spiculated "sun-ray" periosteal reaction and perpendicular bony striae have been described and should not be used to exclude metastasis.[16]

Recognized variants and pitfalls

Early deposits may show only subtle trabecular loss or isolated PDL widening, closely mimicking periodontal or periapical inflammatory disease and leading to misdiagnosis.[13] Dense amalgam and bony cortices can obscure marrow extent, and the true size of a deposit is frequently underestimated on plain imaging.[21]

Confirming skeletal and systemic extent

Cross-sectional imaging better defines marrow and soft-tissue extent than plain films; MRI is preferred for marrow and perineural spread, while CT best demonstrates cortical erosion.[22]

Detecting the deposit and the primary

Whole-body functional imaging is central when metastasis is suspected or a primary is occult. FDG-PET/CT is the preferred study for detecting distant disease and identifying an occult primary, and it improves visualization in the mandible where dental artifact degrades CT.[21][22][23] For bone-seeking evaluation, 18F-sodium fluoride PET/CT and FDG-PET/CT outperform 99mTc-MDP scintigraphy in sensitivity, though scintigraphy relies on osteoblastic activity and may miss purely lytic deposits or show them only as photopenic "cold spots".[20][24][25] Bone scintigraphy remains a reasonable screen to document multifocal skeletal disease when jaw pain is the sentinel complaint.[15][26]

A destructive, ill-defined jaw radiolucency with pain or paresthesia in an adult older than 40—particularly with any cancer history—should raise metastasis first; the key discriminators are absence of an odontogenic epicenter, a ragged non-corticated periphery, and rapid tempo.[3][16] The highest-yield alternatives are other causes of a permeative or periodontal-mimicking lesion.

The highest-risk pitfall is dismissing early metastasis as periodontal or periapical inflammatory disease, since both can show PDL widening and alveolar bone loss; new mental-nerve paresthesia, rapid progression, or a non-healing socket should trigger incisional biopsy rather than continued dental treatment.[1][13] Biopsy with a focused immunohistochemical panel is the decisive step and should precede any assumption of a benign process.[1][10]

Microscopically, the deposit recapitulates its primary: most jaw metastases are adenocarcinoma, followed by other carcinomas, while hepatoid, clear-cell (renal), and papillary (thyroid) patterns point toward specific origins.[6][11][28] Malignant epithelial islands or glands infiltrate marrow and permeate between trabeculae and around tooth roots, correlating with the permeative radiolucency and PDL widening seen on imaging.[13][17]

When morphology alone cannot establish origin, immunohistochemistry is required.[3] A stepwise panel first confirms lineage (pan-cytokeratin for carcinoma; SOX10/S100 for melanoma; CD45 for lymphoid), then subclassifies carcinoma, often using CK7/CK20 coordinates before adding site-specific markers:[10][29]

• TTF-1, napsin A — lung adenocarcinoma (TTF-1 and thyroglobulin/PAX8 for thyroid).[9]
• GATA3, ER/PR, GCDFP-15, mammaglobin — breast.[9]
• PAX8, CA-IX, CD10, RCC marker — renal cell carcinoma.[9]
• NKX3-1, PSA, PSAP — prostate.[9]
• CDX2, SATB2, villin — colorectal/lower gastrointestinal.[9]
• Arginase-1, HepPar-1, glypican-3 — hepatocellular.[9]

Because no single marker is fully sensitive or specific, a focused panel directed by the clinical picture is recommended, and a minority of cases remain unassignable despite full workup, warranting molecular methods such as DNA-methylation or gene-expression profiling.[9][30][31]

Workup and referral

Confirm the diagnosis by incisional biopsy; when the primary is unknown, pursue the occult-primary pathway—chest/abdomen/pelvis CT, bone imaging, directed IHC, mammography in women, and PSA in men—coordinated with medical oncology.[9][10] FDG-PET/CT is the preferred staging study for distant disease and occult-primary localization.[22][23]

Definitive treatment and selection factors

Treatment is governed by overall disease burden rather than the jaw lesion alone.[2][3]

• Disseminated disease (most patients): palliative systemic therapy appropriate to the primary, with local radiotherapy, analgesia, and bone-targeted agents for pain, pathologic-fracture risk, and function.[3][7]
• Apparently solitary deposit: surgical resection, with or without radiotherapy/chemotherapy, may be considered for durable local control or symptom relief.[3][32]
• Supportive dental care and management of treatment-related oral complications remain important throughout.[19]

Recurrence, surveillance, and prognosis

A jaw metastasis signals advanced disease and a poor prognosis. Reported median survival is approximately 6–8 months, and historical five-year survival is near 10%.[3][4][12] Outcome is driven chiefly by the biology and stage of the primary and the extent of systemic spread rather than by local jaw therapy; some primaries (for example, certain thyroid or renal tumors) behave more indolently.[11][32] Surveillance is integrated into oncologic follow-up, with imaging directed by the primary tumor and symptoms.[22]